Chimeric: Media Thread, page-819

Yes, agree saftey and OBD are the main goal of the phase 1.

But like with most oncology phase 1 trials, the patient population aren't healthy volunteers, they're actual patients. Which means we also get to look for efficacy signals (responses).

Most of the oncology bios I follow don't get much of a SP kick from dose escalation/cohort safety announcements. What everyone is waiting for is more efficacy data, that's what excites the market and can set off a decent re-rate. Which is what we need to raise any meaningful cash.

Because CHM 1101 trial results are now at least a year away, we need either CDH17 or NK ADVENT (or both) to deliver some stellar interim results ASAP.

Otherwise well be giving away half the company to raise 2-3 quarters cash.

We really have got ourselves stuck in black hole. Let's hope the BoD can pull something out of the hat.